Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cutia Therapeutics ( (HK:2487) ).
Cutia Therapeutics announced that its investigational product CU-20101, a botulinum toxin type A injection for treating moderate to severe glabellar lines, has delivered positive topline results in a Phase III clinical trial in China. In a randomized, multi-center, double-blind trial with BOTOX as the reference drug, CU-20101 met primary and secondary efficacy endpoints by demonstrating non-inferiority in wrinkle reduction across investigator, participant and independent committee assessments, and showed a favorable safety profile comparable to BOTOX with no treatment-related serious adverse events. Manufactured without animal-derived materials, CU-20101 is expected to offer safety advantages by eliminating certain infection and allergy risks, and, if successfully developed and commercialized, would further strengthen Cutia’s dermatology portfolio and support its efforts to gain share in China’s fast-growing aesthetic medicine market.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a Cayman Islands-incorporated biopharmaceutical group focused on dermatology and skin treatments. The company is building a diversified portfolio of skin-related products aimed at addressing broad demand in the aesthetic and therapeutic dermatology market in China.
Average Trading Volume: 358,506
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.74B
Find detailed analytics on 2487 stock on TipRanks’ Stock Analysis page.